Trusted by over 10K subscribers
    Free & discreet shipping on all prescriptions
    Affordable pricing with no hidden fees
    FDA-regulated pharmacies
    100% online process
    Trusted by over 10K subscribers
    Free & discreet shipping on all prescriptions
    Affordable pricing with no hidden fees
    FDA-regulated pharmacies
    100% online process
    Trusted by over 10K subscribers
    Free & discreet shipping on all prescriptions
    Affordable pricing with no hidden fees
    FDA-regulated pharmacies
    100% online process
    HomeMedication GuideAmylin Analogue (Long-Acting) safety
    Long-acting amylin analogue — investigationalInvestigational / Not FDA-Approved

    Linc (Amylin Analogue): Patient Information & Safety Notes

    Also known as Linc amylin

    Other names: linc-amylin, long-acting-amylin-analog

    Linc is described as a long-acting amylin analogue designed to suppress appetite, slow gastric emptying, and reduce food intake. Pramlintide (Symlin) is an FDA-approved amylin analogue for diabetes. Linc as a long-acting variant is investigational and not FDA-approved.

    NOT FDA-approved. Linc is an investigational long-acting amylin analogue. It is described as an adjunct to GLP-1 agonists. Its safety and efficacy in humans have not been established in completed clinical trials. Do not assume availability.
    Reviewed by the OmniRx Health clinical team•Last reviewed Jul 4, 2026

    In plain language

    What Amylin Analogue (Long-Acting) is used for

    • Investigated as an adjunct to GLP-1 agonist therapy for additional weight loss (not yet validated)

    Taking this medicine

    How it is administered

    • Subcutaneous injection

    Read before you decide

    Risks and precautions

    Risks and warnings

    • Nausea, constipation, vomiting (class effects of amylin analogues)
    • Injection site irritation
    • Hypoglycemia when used with insulin (amylin class interaction)
    • Safety profile in humans not established for this specific long-acting formulation

    Who should not take it

    • Active gastroparesis or clinically significant gastrointestinal disease (amylin slows gastric emptying)
    • Hypoglycemia unawareness (amylin analogue use with insulin can worsen hypoglycemia awareness)
    • Pregnancy or breastfeeding (insufficient safety data)

    Common questions

    Patient questions

    Is Linc FDA-approved?

    No. Linc is an investigational compound not approved by the FDA. An approved amylin analogue (pramlintide/Symlin) exists for use with insulin in type 1 and type 2 diabetes, but Linc is a different long-acting formulation with no completed human clinical trials. A licensed provider can discuss evidence-based weight management options.

    How is Linc different from pramlintide (Symlin)?

    Pramlintide (Symlin) is an FDA-approved synthetic amylin analogue taken at mealtimes to reduce postprandial glucose excursions. Linc is described as a longer-acting variant intended for less-frequent dosing. Linc has not completed human clinical trials and is not FDA-approved for any indication.

    Explore treatment hubs

    This information is educational — not medical advice.

    This page is provided for general educational purposes and summarizes publicly available data from sources such as the U.S. Food & Drug Administration. It is not a substitute for the judgment of a licensed clinician and should not be used to start, stop, or change any medication. It may be incomplete or out of date, and individual circumstances vary. Always talk with your prescriber or pharmacist about your specific medications and health conditions. If you think you may have a medical emergency, call 911.